The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab (pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.
 
Yves Fradet
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca/MedImmune; Bayer; Merck; Roche Canada; Sanofi
Research Funding - Astellas Pharma
 
Joaquim Bellmunt
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Merck; Novartis; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Pfizer
 
Ronald De Wit
Honoraria - Lilly; Merck Sharp & Dohme; Roche/Genentech; Sanofi
Consulting or Advisory Role - Lilly; Merck Sharp & Dohme; Roche/Genentech; Sanofi
Research Funding - Bayer (Inst); Sanofi (Inst)
 
David J. Vaughn
Research Funding - Merck Sharp & Dohme; Roche/Genentech
 
Jae-Lyun Lee
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Eisai
Research Funding - Bristol-Myers Squibb; Exelixis; Janssen; Novartis; Pfizer; Roche/Genentech
 
Lawrence Fong
Consulting or Advisory Role - Atreca; IDEAYA Biosciences; MIODx
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Pfizer; UpToDate
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Caris Life Sciences; Fujifilm; Genentech/Roche; HERON; Pfizer; Tolero Pharmaceuticals
Speakers' Bureau - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Sanofi
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; US Oncology
 
Miguel A. Climent
Honoraria - Bayer; Bristol-Myers Squibb; Janssen; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Janssen; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Roche; Sanofi; TYME
Research Funding - Agensys; Astellas Medivation; AstraZeneca; Bayer; Dendreon; Endocyte; Genentech; Innocrin Pharma; Johnson & Johnson; Lilly; MedImmune; Merck; Millennium; Novartis; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Seagen; Sotio
Expert Testimony - Celgene; sanofi
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - alligent; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Corvus Pharmaceuticals; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Ipsen; Merck; Novartis; Peloton Therapeutics; Pfizer; Prometheus; Roche/Genentech
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
 
Andrea Necchi
Consulting or Advisory Role - AstraZeneca; Bayer; Clovis Oncology; Merck Sharp & Dohme; Roche
Research Funding - Amgen (Inst); AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pierre Fabre; Roche
 
Winald R. Gerritsen
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; CureVac; Janssen-Cilag; Merck Sharp & Dohme; Sanofi
Speakers' Bureau - Merck Sharp & Dohme
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen-Cilag (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Merck Sharp & Dohme
 
Howard Gurney
Honoraria - Pfizer
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme (Inst)
 
David I. Quinn
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Peloton Therapeutics; Pfizer; Piramal Life Science; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; Eisai; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Peloton Therapeutics; Pfizer; Piramal Life Science; Sanofi
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Sanofi (Inst)
 
Stephane Culine
Consulting or Advisory Role - Janssen; Roche
Research Funding - Astellas Pharma; MSD; Roche
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen
 
Cora N. Sternberg
Honoraria - Astellas Pharma; AstraZeneca; Ipsen; Pfizer; Sanofi
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Ferring; Janssen; Lilly; MSD; Novartis
 
Kijoeng Nam
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Tara L. Frenkl
Employment - Aevi Genomic Medicine (I); Amicus Therapeutics (I); Merck
Leadership - VenatoRx (I)
Stock and Other Ownership Interests - AstraZeneca; AstraZeneca (I); GlaxoSmithKline; GlaxoSmithKline (I); Merck; Merck (I)
Research Funding - Merck
Travel, Accommodations, Expenses - Aevi Genomic Medicine (I); Amicus Therapeutics (I); Merck
 
Rodolfo F. Perini
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EMD Serono; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Lilly; Merck; Novartis; Pfizer; Roche; Roche/Genentech; Urogen pharma
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Roche/Genentech; Urogen pharma